DF/HCC Kidney Cancer SPORE

DF/HCC 肾癌孢子

• 批准号: 9336244
• 负责人: WILLIAM G. KAELIN
• 金额: $ 230万
• 依托单位: BETH ISRAEL DEACONESS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-18 至 2020-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9336244
• 关键词: Address; Angiogenesis Inhibitors; Basic Science; Biometry; Boston; Cancer Biology; Cancer Center; Center Core Grants; Chromatin; Clear Cell; Clinical; Clinical Data; Clinical Research; Communities; Computational Biology; Critical Pathways; Dana-Farber Cancer Institute; Development; Device or Instrument Development; Evaluation; FRAP1 gene; Funding; Future; General Hospitals; Genetic Markers; Genomics; Goals; Grant; Hospitals; Immunotherapy; Incentives; Institutes; Institution; Israel; Knowledge; Laboratory Scientists; Massachusetts; Medical center; Mentors; Mission; Molecular; Monitor; Mutation; New Agents; Oncogenic; Outcome; Pathology; Pathway interactions; Patients; Pediatric Hospitals; Physicians; Pre-Clinical Model; Prognostic Marker; Program Development; Public Health Schools; Regulator Genes; Renal carcinoma; Reporting; Research; Research Infrastructure; Research Personnel; Resistance; Scientist; Seasons; Secondary to; Specialized Program of Research Excellence; Stream; Talents; Technology; Testing; The Cancer Genome Atlas; Therapeutic Index; Time; Tissues; Toxic effect; Translational Research; Treatment outcome; Woman; anticancer research; base; career; career development; clinical investigation; drug development; effective therapy; genetic analysis; immune checkpoint; improved; knowledge base; medical schools; member; molecular marker; novel; outcome forecast; patient population; predicting response; programs; public health relevance; resistance mechanism; success; targeted agent; tool; treatment response

DESCRIPTION (provided by applicant): This application represents a resubmission of a competing renewal application for a Specialized Program of Research Excellence (SPORE) in Kidney Cancer from the Kidney Cancer Program of Dana-Farber/Harvard Cancer Center (DF/HCC). The DF/HCC Kidney Cancer SPORE has been funded for two cycles since 2003. DF/HCC is comprised of the following institutions: Beth Israel-Deaconess Medical Center (BIDMC); Dana- Farber Cancer Institute (DFCI); Harvard Medical School; Harvard School of Public Health; Brigham and Women's Hospital; Massachusetts General Hospital (MGH); and Children's Hospital of Boston. In addition to the institutions in the DF/HCC, the Whitehead Institute at Massachusetts Institute of Technology and Georgetown-Lombardi Cancer Center (GLCC) are collaborating institutions in this grant. The DF/HCC Kidney Cancer SPORE has its administrative base at the BIDMC. Dr. David McDermott, who has led the DF/HCC Kidney Cancer Program and SPORE since 2012 is joined as SPORE Director by Dr. William Kaelin, a laboratory scientist at DFCI and Associate Director for Basic Science in the DF/HCC. Drs. McDermott and Kaelin report directly to Dr. Edward Benz, Director of DF/HCC and President of DFCI. The DF/HCC Kidney Cancer SPORE has a broad and deep talent base and there is extensive institutional commitment. We take advantage of a large patient population and cutting edge technologies that are available to us as part of DF/HCC. We propose 4 Projects which address critical problems in kidney cancer and have translational components. They focus on identifying effective strategies for targeting: HIF2α, the dominant oncogenic driver of clear-cell RCC (Project 1), angiogenesis inhibitor resistance mechanisms, which undermine the most commonly applied therapies (Project 2) and improving the therapeutic index of agents targeting the mTOR (Project 3) and immune checkpoint pathways (Project 4). The projects are supported by three Cores - an Administrative Core, a Biostatistics and Computational Biology Core, and a Tissue Acquisition, Pathology and Clinical Data Core. We also have a highly successful Career Development Program that selects talented physician scientists and mentors them to independence as well as a Developmental Projects Program that generates new ideas for the SPORE in the future. The existence of the SPORE has provided opportunities and incentives to extend basic science and clinical research ideas into the translational realm and facilitated the entry of young, as well as some seasoned, investigators into the kidney cancer field where they have made major contributions.

描述（由申请人提供）：本申请代表Dana-Farber/哈佛癌症中心（DF/HCC）肾癌项目的肾癌卓越研究专业项目（SPORE）的竞争性更新申请的重新提交。DF/HCC肾癌孢子自2003年以来已资助了两个周期。DF/HCC由以下机构组成：贝斯以色列女执事医疗中心（BIDMC）;达纳-法伯癌症研究所（DFCI）;哈佛医学院;哈佛公共卫生学院;布里格姆妇女医院;马萨诸塞州总医院（MGH）;波士顿儿童医院。除了DF/HCC中的机构外，马萨诸塞州理工学院怀特黑德研究所和乔治城-隆巴迪癌症中心（GLCC）也是该资助的合作机构。DF/HCC肾癌孢子在BIDMC有其行政基础。自2012年以来一直领导DF/HCC肾癌项目和SPORE的大卫·麦克德莫特博士与DFCI实验室科学家兼DF/HCC基础科学副主任威廉·凯林博士一起担任SPORE主任。McDermott博士和Kaelin博士直接向DF/HCC主任兼DFCI总裁Edward Benz博士报告。DF/HCC肾癌孢子拥有广泛而深厚的人才基础，并有广泛的机构承诺。我们利用了大量的患者群体和作为DF/HCC的一部分提供给我们的尖端技术。我们提出了4个项目，解决肾癌的关键问题，并有翻译组件。他们专注于确定有效的靶向策略：HIF 2 α，透明细胞RCC的主要致癌驱动因素（项目1），血管生成抑制剂耐药机制，这会破坏最常用的疗法（项目2），并提高靶向mTOR（项目3）和免疫检查点通路（项目4）的药物的治疗指数。这些项目由三个核心支持-行政核心，生物统计学和计算生物学核心，以及组织采集，病理学和临床数据核心。我们还有一个非常成功的职业发展计划，选择有才华的医生科学家，并指导他们独立，以及发展项目计划，为未来的SPORE产生新的想法。SPORE的存在提供了机会和激励，将基础科学和临床研究理念扩展到转化领域，并促进了年轻人以及一些经验丰富的研究人员进入肾癌领域，他们做出了重大贡献。